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Abstract: Diastrophic dysplasia (DTD) is a rare osteochondrodysplasia characterized by short-limbed
short stature and joint dysplasia. DTD is caused by mutations in SLC26A2 and is particularly common
in the Finnish population. However, the disease incidence in Finland and clinical features in affected
individuals have not been recently explored. This registry-based study aimed to investigate the
current incidence of DTD in Finland, characterize the national cohort of pediatric subjects with DTD
and review the disease-related literature. Subjects with SLC26A2-related skeletal dysplasia, born
between 2000 and 2020, were identified from the Skeletal dysplasia registry and from hospital patient
registry and their clinical and molecular data were reviewed. Fourteen subjects were identified.
Twelve of them were phenotypically classified as DTD and two, as recessive multiple epiphyseal
dysplasia (rMED). From the subjects with available genetic data, 75% (9/12) were homozygous for
the Finnish founder mutation c.-26+2T>C. Two subjects with rMED phenotype were compound
heterozygous for p.Arg279Trp and p.Thr512Lys variants. The variable phenotypes in our cohort
highlight the wide spectrum of clinical features, ranging from a very severe form of DTD to milder
forms of DTD and rMED. The incidence of DTD in Finland has significantly decreased over the past
decades, most likely due to increased prenatal diagnostics.
Keywords: SLC26A2; diastrophic dysplasia; multiple epiphyseal dysplasia; phenotype; skeletal dys-
plasia
1. Introduction
Diastrophic dysplasia (DTD, MIM #222600) is a rare autosomal recessive chondrodys-
plasia caused by biallelic mutations in the sulfate transporter gene (SLC26A2), also known
as diastrophic dysplasia sulfate transporter (DTDST) gene. The gene locates in distal chro-
mosome 5q and encodes a sulfate transporter [1]. This transmembrane sulfate transporter
is important for the uptake of sulfate into chondrocytes, in order to maintain adequate
sulfation of proteoglycans and has an important role in endochondral bone formation.
SLC26A2 is expressed in several tissues with particularly high expression in developing
and mature cartilage and epithelial tissues [2–4]. Mutations lead to impaired sulfate trans-
portation through cell membranes, intracellular sulfate depletion and insufficiently sulfated
proteoglycans [5]. The phenotypic severity of DTD has been related to residual sulfate
uptake capacity and degree of proteoglycan under-sulfation [6]. Mutations in SLC26A2 lead
to a wide spectrum of both lethal and non-lethal skeletal dysplasia. The lethal conditions
include achondrogenesis type 1B (ACG1B, MIM #600972) and atelosteogenesis type 2 (AO2,
MIM #256050. The non-lethal conditions are diastrophic dysplasia (DTD) and recessive
multiple epiphyseal dysplasia (rMED, MIM #226900) [7,8]. These disorders are inherited
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in an autosomal recessive manner; all heterozygous mutation carriers are asymptomatic.
SLC26A2 is the only gene linked to DTD [9].
DTD is found in almost all populations but is exceptionally common in the Finnish
population. In 1990, about 160 subjects with DTD were known in Finland [10]. Over
250 subjects with DTD have been published elsewhere [11]. Approximately 90% of the
individuals with DTD in Finland carry the Finnish founder mutation c.-26+2T>C, either
in homozygosity or compounded with another SLC26A2 mutation [12]. The p.Arg279Trp
mutation is the most frequent mutation in non-Finnish populations; it causes rMED in
homozygous state and usually DTD in compound heterozygous state [13]. Other common
mutations are p.Cys653Ter and p.Arg178Ter [8,9,13].
Clinical features of DTD include short stature with limb shortening, contractures of
large joints, spinal deformities, cleft palate, clubfoot, cystic swelling of the external ear
and deformities of the hands. The median adult height is 136 cm for males and 129 cm for
females [14]. DTD causes significant physical difficulties. Limb shortness and tightness of
ligaments and joint capsules lead to limited joint mobility [9]. Flexion contractures of the
knees, osteoarthrosis, scoliosis, foot deformities and obesity cause walking difficulties [15].
Physical difficulties in daily life affect the quality of life, together with economic and
social challenges [16]. Clinical findings of the milder phenotype rMED are normal/mildly
shortened stature, joint contractures, mild hand deformity, double-layered patellae and
clubfoot [17–20]. The clinical features partly overlap with those of DTD.
Radiological findings in DTD include shortened long bones with metaphyseal flaring,
flat epiphyses, kyphoscoliosis, cervical kyphosis, bowed radius and tibia, proximally
situated “hitchhiker” thumb with shortness of the first metacarpal, brachydactyly and
ulnar deviation of fingers. The diagnosis of DTD is made by a combination of clinical and
radiological findings and confirmed with molecular genetic testing targeting the SLC26A2
gene. Prenatal diagnosis can be performed by ultrasound and genetic testing [9,21].
There is currently no curative treatment for DTD. The affected individuals are mainly
treated with physiotherapy and corrective orthopedic surgery [22–25]. However, recent
animal studies have shown promising results from treatment with N-acetylcysteine (NAC),
which acts as an intracellular source of sulfate. Dtd mice treated with NAC showed
an increase in cartilage proteoglycan sulfation and improvement of the skeletal pheno-
type [26,27]. These findings suggest that NAC could have some potential for pre- and
postnatal pharmacological treatment for subjects with DTD. Another study in mice found
a novel therapeutic target in the lethal forms of SLC26A2-related chondrodysplasias by dis-
covering overactive fibroblast growth factor 3 (Fgfr3) signaling in slc26a2−/− mice. FGFR3
signaling is an important pathway in the regulation of chondrocyte growth. Suppression
of Fgfr3 signaling by inhibition of Fgfr3 or phosphorylation of the downstream effectors
improved cartilage growth in vitro and pathological characteristics of slc26a2−/− newborn
mice [28], suggesting that this could be another treatment target in DTD.
The incidence of DTD in Finland has not been explored recently. This study aimed to
investigate the incidence of DTD in Finland during the recent years, clinically characterize a
cohort of Finnish pediatric DTD patients, and review the current literature on this disorder.
2. Materials and Methods
This retrospective register study was carried out at Children’s Hospital, Helsinki Uni-
versity Hospital, Finland. This study is part of an ongoing research program investigating
the epidemiological, genetic and clinical features of skeletal dysplasia in the Finnish popu-
lation. The care of children with skeletal dysplasia has for several years been centralized to
Helsinki University Hospital. In addition, several nationwide studies on DTD have been
carried out in Helsinki over the years, and these data have been systematically collected
in the Finnish Skeletal dysplasia registry. We reviewed the Skeletal dysplasia registry for
all subjects with DTD born during years 1950–2020 and the hospital patient register for
all those with SLC26A2-associated skeletal dysplasia born in 2000 or later. Clinical and
molecular data were collected from hospital records for all subjects born in 2000–2020.
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Growth data were compared with Finnish growth standards [29]. Ethical approval for this
study was obtained from the research ethics committee of the Hospital District of Helsinki
and Uusimaa.
3. Results
3.1. Number of Finnish DTD Subjects Born in 1950–2020
Figure 1 presents the number of Finnish subjects with DTD in the national skeletal
dysplasia registry born in 1950–2020. We identified a total of 132 subjects. Our pediatric
cohort, representing those born during 2000–2020, includes 14 individuals. There was a
continuous downward trend in the number of children born with DTD over the years.
While in 1950–1990 there were 22–35 new affected subjects born each decade, the number
has since then diminished to on average 1 or no new subjects yearly (Figure 1).
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3.2. Clinical and Molecular Description of the Pediatric Cohort
We identified 14 Finnish subjects in 13 families (seven males and seven females), born
in 2000–2020, in the national skeletal dysplasia registry and hospital registry. In two of
these individuals, a diagnosis of DTD was initially assumed, but the diagnosis was later
confirmed to be rMED. One child with a very severe form of DTD deceased at the age of
8 days, while the more mildly affected sibling survived. The median age of the remaining
13 subjects was 13.5 years (range 5.3–20.8 years).
Table 1 presents the genetic information, clinical phenotype and length/height SDS at
birth, age 1 year and age 5 years for the affected children in our cohort. Genetic information
was available for 12 of them. Nine were homozygous for the Finnish SLC26A2 founder
mutation (c.-26+2T>C). One subject with a milder form of DTD was heterozygous for the
Finnish founder mutation, but information about the second mutation was not available.
However, the clinical presentation was typical for DTD. Two subjects with rMED phenotype
were compound heterozygous for p.Arg279Trp and p.Thr512Lys variants; these subjects
have been previously described [30,31].
Table 2 presents growth data at birth for the subjects with DTD and rMED. The
children had usually a significant growth deficit already at birth. Median length SDS at
birth was −4.1 for girls and −4.5 for boys with DTD, and −1.7 for the boys with rMED.
The growth failure progressed during the first year. Median length SDS at age 1
was −6.25 for girls and −6.5 for boys with DTD, and −1.45 for boys with rMED. The
median decrease in length SDS from birth to age 1 was 1.8 for girls and 2.1 for boys with
DTD. Median height SDS at age 5 was −5.5 for girls and −4.7 for boys with DTD. Median
length-adjusted weight (weight-for-length; normal range −20%–+20%) at age 1 was 22%
(range 10–49) for girls, 23% (range 20–33) for boys with DTD and 5.5% (range 4–7) for boys
with rMED. Median weight-for-length at age 5 was 17% (range 12–25) for girls, 24% (range
14–53) for boys with DTD and 8% (range 7–9) for boys with rMED.
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1 N/A N/A DTD −4.2 N/A N/A
2 c.-26+2T>C c.-26+2T>C DTD −4.0 −6.9 −5.6
3 c.-26+2T>C c.-26+2T>C DTD −5.9 −7.4 −7.2
4 c.-26+2T>C c.-26+2T>C DTD −5.3 −7.6 −5.4
5 c.-26+2T>C c.-26+2T>C DTD −2.9 −6.5 −5.1
6 c.-26+2T>C c.-26+2T>C DTD −3.5 −5.4 −4.7
7 c.-26+2T>C c.-26+2T>C DTD −3.7 −4.5 N/A
8 * c.-26+2T>C c.-26+2T>C DTD N/A N/A N/A
9 c.-26+2T>C c.-26+2T>C DTD −3.5 −5.3 −2.9
10 * c.-26+2T>C c.-26+2T>C DTD −6.3 −9.2 −7.9
11 N/A N/A DTD −4.4 −6.2 N/A
12 c.-26+2T>C N/A DTD N/A N/A −4.0
13 Arg279Trp Thr512Lys rMED −2.2 −2.6 −2.9
14 Arg279Trp Thr512Lys rMED −1.1 −0.3 N/A
N/A = not available; * siblings.
Table 2. Growth data at birth for children affected with DTD and rMED. Data presented as median
(range).
Boys Girls
DTD n = 4 n = 6
Length (cm) 42.5 (39–44.5) 43 (39.5–45)
Weight (g) 3310 (2615–3570) 3390 (2525–3900)
Head circumference (cm) 36.5 (35–37) 35.5 (32–38)
rMED n = 2 n = 0
Length (cm) 48 (47–49)
Weight (g) 3680 (3230–4120)
Head circumference (cm) 36 (35–37)
Median height SDS at last follow-up was −5.5 (range −4.5 to −6.8) for girls at median
age 12 years (range 10–17 years), −4.1 (range −3.2 to −8.8) for boys with DTD at median
age 13 years (range 9–16 years) and −2.9 (range −2.9 to −2.9) for boys with rMED at
median age 12.5 years (range 5–20 years). Median weight-for-length at last follow-up was
35% (range 14–118) for girls, 53% (range 11–100) for boys with DTD, and 23.5% (range
7–40) for boys with rMED. These values indicate that the subjects with DTD have severe
short stature, but the degree of growth failure varies considerably despite similar causative
SLC26A2 variants in most of the subjects.
Information about the time of diagnosis was available for 13 children; in 77% (10/13)
DTD was suspected during pregnancy and in 23% (3/13) at birth. Ultrasound screening
found abnormalities during pregnancy in ten subjects; in three, nuchal translucency ultra-
sound screening showed abnormalities and in all ten, structural ultrasound showed short
limbs and suspicion of a developmental disorder. The diagnosis of DTD was prenatally
confirmed from amniotic fluid sample in two subjects. In the remaining eight subjects,
diagnosis of DTD was confirmed after birth. The suspicion of DTD at birth in the three
subjects was based on clinical features like short limbs, clubfoot, cleft palate and hand
abnormalities. Birth records were available for 13 subjects. Median duration of pregnancy
Genes 2021, 12, 714 5 of 12
was 39 + 1 weeks. Five subjects (36%) had respiratory insufficiency after birth; three of
them were treated at the intensive care unit and one had severe pulmonary hypertension.
Table 3 presents the prevalence of clinical manifestations in our cohort. Hand abnor-
malities were present in all subjects; the most common findings were symphalangism of
the fingers (n = 7), hitchhiker’s thumb/abduction of the thumb (n = 7), flexion tendency
of the fingers (n = 6) and lack of proximal interphalangeal joints (n = 1). Cleft palate was
present in 64%. Bipartite uvula was mentioned in four cases and one subject had a missing
uvula. Three children had naevus flammeus in forehead, ten had small chin and five had
auricular abnormalities (swelling/deformities).
Seven subjects had bilateral club foot deformity, one had unilateral club foot and
two had metatarsus adductus deformity. The prevalence of knee problems was high;
valgus deformity (86%), lateral position of patella (79%) and absence/laxity of the anterior
cruciate ligament (ACL) (71%) were the main features. Five children (36%) had scoliosis.
The children obtained their diagnosis of scoliosis at 0–14 years of age. One child had a
rapidly progressing scoliosis at age 1 year. Pronounced lumbar lordosis was present in
eight subjects (57%) and cervical kyphosis was present in 11 subjects (79%). The severity of
cervical kyphosis varied from mild to severe. The kyphosis had resolved spontaneously in
four children at the age of 2–7 years. One child required an operation and Glisson’s skull
traction.
Table 3. Prevalence of clinical features in the Finnish children with SLC26A2-related skeletal dysplasia.
Values are given for the whole cohort and separately for children with DTD and rMED.
Clinical Features All (n = 14) DTD (n = 12) rMED (n = 2)
Hand abnormalities 100% 100% 100%
Cleft palate 64% 67% 50%
Naevus flammeus 21% 25% 0%
Small chin 71% 75% 50%
Auricular abnormality 36% 33% 50%
Club foot 57% 58% 50%
Other foot deformity 21% 17% 50%
ACL absence/laxity 71% 75% 50%
Lateral position of patella 79% 83% 50%
Patellar luxation 57% 58% 50%
Valgus deformity 86% 83% 100%
Cervical kyphosis 79% 83% 50%
Scoliosis 36% 33% 50%
Lumbar lordosis 57% 58% 50%
Two children with DTD had a diagnosis of early-onset osteoarthrosis; one had rapidly
progressive arthrosis and ankylosis of the left hip at age 10 and the other had arthrosis
of the lateral knee condyle at age 17. The most common surgeries performed were knee
operations (n = 9), cleft palate (n = 8), club foot (n = 7) and achilles tenotomy (n = 6). Neck
and spine operations were performed for one child.
3.3. Literature Review
Next, we performed a literature search in Pubmed to identify reports, written in
English, describing non-Finnish SLC26A2-related DTD and rMED subjects and cohorts
during 2000–2021. Table 4 presents the genetic and clinical findings of these previously
reported subjects. The Finnish founder mutation c.-26+2T>C was rare and described in
homozygosity only in one individual with DTD. Compounded with the most common
SLC26A2 variant, Arg279Trp it gave rise to rMED or an intermediate phenotype. The
Arg279Trp in turn led to rMED in homozygosity (Table 4).
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Table 4. Genetic and clinical findings in previously reported non-Finnish subjects and cohorts with SLC26A2-related DTD and rMED. Empty spaces indicate that detailed data were not






























Arg279Trp Arg279Trp rMED 27 15% 30% 7% 4% 41% 7% 4% 4% 7% [13,17,32,33]
Arg279Trp Arg178Ter DTD 8 88% 100% 25% 100% 88% 13% 88% 63% 38% [13,34]
c.-26+2T>C Arg279Trp rMED 4 25% 25% 25% 0% 25% 25% 50% 75% [35]
c.-26+2T>C Arg279Trp Intermediate 4 75% 75% 50% 50% 50% 25% 50% 25% 25% [36,37]
Cys653Ser Cys653Ser rMED 6 83% 17% 17% 50% 50% [18,38,39]
Cys653Ser Ala715Val Intermediate 3 100% 100% 0% 0% 67% 33% 33% 67% 67% [40]
Arg279Trp c.727-1G>C Intermediate 2 100% 100% 0% 100% 100% 100% 50% 50% [13]
Leu275Pro Leu400Phe rMED 2 50% 0% 50% 50% [41]
Val162fs Asp385Asn rMED 1 100% 0% 0% 100% 100% 0% 0% 0% [42]
c.-26+2T>C c.-26+2T>C DTD 1 100% 100% 100% 100% [35]
Arg279Trp Asn425Asp DTD 1 100% 100% 100% 100% 100% 100% 100% 100% [13]
Arg279Trp Ser522Phe rMED 1 100% 0% 100% 100% [43]
Thr266Ile Val340del Intermediate 1 100% 100% 100% [44]
Arg279Trp Thr512Lys rMED 1 0% 100% 100% 0% 0% 0% [35]
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4. Discussion
This study investigated the registry-based incidence of DTD in Finland in subjects
born between 1950 and 2020 and describes the clinical features of DTD in a non-selected
group, including all Finnish DTD subjects born between 2000 and 2020. DTD has been the
most prevalent skeletal dysplasia in Finland with reported disease incidence of 1:22,000 [11],
compared to the estimated incidence of 1:100,000 in non-Finnish populations [9]. However,
the incidence of DTD has not been recently explored. We noticed a significant decrease in
the number of DTD subjects over the past decades. Ten children with DTD were born in
2000–2010 and only 4 children in 2010–2020. The decreased number of subjects with DTD
is likely explained by increased prenatal diagnostics.
Our Finnish pediatric cohort comprised 14 subjects with SLC26A2-related skeletal
dysplasia; 75% of all subjects and 90% of those with the DTD phenotype were homozygous
for the Finnish founder mutation and one was (compound) heterozygous for the founder
mutation. This is in line with previous reports [12], and characteristic of the diseases belong-
ing to the ‘Finnish Disease Heritage’, caused by recessive founder mutations. The SLC26A2
Finnish founder mutation is a splice-site mutation, usually found in homozygosity, which
is classified as a severe mutation [12]. It causes DTD when homozygous, mild DTD/rMED
in compound heterozygosity with mild alleles and ACG1B/AO2 in combination with
severe alleles [36]. In our study, the patient with heterozygous Finnish founder mutation
had a milder form of DTD, but information about the second variant was not available as
genetic testing was performed elsewhere.
Two subjects with rMED phenotype had a combination of p.Arg279Trp and p.Thr512Lys.
Their clinical and radiological findings have been described in detail previously [30,31].
These subjects presented with clinical features typical for rMED like mildly shortened
stature, joint contractures, short limbs, clubfeet and hand deformities, but also cleft palate,
cervical kyphosis and cystic swelling of the external ears. The p.Thr512Lys is a rare severe
mutation, causing lethal form of dysplasia in homozygosity, DTD when compounded
with the Finnish founder mutation and rMED when compounded with p.Arg279Trp. The
p.Arg279Trp is a mild mutation reported to have considerable residual transporter activity
and this milder mutation likely rescues the phenotype when compounded with the more
severe mutation p.Thr512Lys [31,45].
The growth disturbance in DTD has its onset prenatally. Proteoglycans are important
in the development and function of the growth plate. Animal studies have shown that
slc26a2 has multiple roles in chondrocyte biology and that proteoglycan undersulfation
causes decreased chondrocyte proliferation and lack of terminal differentiation. These
factors have been suggested to contribute to reduced bone growth in DTD [2,4,46,47]. In
our cohort, all children with DTD phenotype had a short stature. They were slightly shorter
at birth compared to growth data from a large study from 1997 on 121 Finnish subjects with
DTD, which reported a median birth length of 45.4 cm for boys and 45.0 cm for girls with
DTD [14]. In our cohort head circumference at birth was normal. The growth failure in
DTD is progressive with a first deviation during the first year [14]. This deviation was also
seen in our study. In our pediatric cohort, median height SDS at last-follow-up was −5.5
for girls and −4.1 for boys with DTD (at median age of 12, and 13 years, respectively). We
observed variability in the severity of growth failure among children with DTD with the
same mutation. Other factors, like the degree of spine deformities and joint contractures
can affect the height and these progressive clinical features can also account for part of
the progressive growth failure [14]. The children with rMED had mildly shortened stature
(−2.9 SD) at last follow-up.
The most common clinical features in this cohort, apart from short stature, were hand
abnormalities. Other common clinical findings were cervical kyphosis, valgus deformity,
lateral position of the patella, small chin and ACL absence/laxity; these manifestations
were found in over 70% of the patients. Cleft palate, club foot, patellar luxation and lumbar
lordosis were found in over half of the patients. The prevalence of cleft palate in our cohort
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(64%) was comparable to previous Finnish studies [48–50] and higher than the prevalence
of 37.5% observed in classical DTD patients in a Portuguese cohort [13].
Spinal deformities are often associated with DTD [51]. Cervical kyphosis was highly
prevalent in our cohort (79%). We observed varying severity of cervical kyphosis; in
four subjects the kyphosis had resolved by the age of 7, one patient required operation
and one child with very severe kyphosis deceased neonatally. This is in line with earlier
studies showing that cervical kyphosis is common in childhood but tends to resolve with
age [52,53]. Even severe forms of cervical kyphosis have been treated with beneficial
and long-lasting results [54], but cervical kyphosis may in rare cases progress to extreme
degrees, and cause spinal cord compression and death [52]. Scoliosis was present in
36% of our cohort. Previous studies have reported scoliosis in 37–90% of patients with
DTD [51,55–57]. Scoliosis in DTD has shown variable natural history and can be classified
into early-progressive, idiopathic-like and mild non-progressive [55]. Pronounced lumbar
lordosis was found in over half of our study subjects. This prevalence was slightly higher
than reported earlier [58]. Due to these significant spinal problems, the affected individuals
should be carefully followed by a spine specialist.
Knee problems like early deformation, instability and flexion contractures are very
common in DTD. The range of motion usually decreases already before the age of five
and the knees show early degenerative changes from age six years onwards [59,60]. The
children in our cohort showed high prevalence of valgus deformity and ACL absence/laxity,
in line with previous studies [59,60]. Patellar luxation was seen in over half of the cohort.
This is similar with a study that found patellar luxation in 63% of children with DTD [61].
More than one third of the children had respiratory problems as newborns. One child
had a very severe form of DTD with severe cervical kyphosis, scoliosis and pulmonary
hypoplasia leading to severe pulmonary hypertension and neonatal death. DTD has been
associated with increased perinatal mortality, mainly because trachea- and broncho-malasia,
and severe cervical kyphosis causing respiratory problems [53,58]. In the absence of severe
complications in early childhood, individuals with DTD have good life expectancy [58].
An overlap between the phenotypes of the SLC26A2 dysplasia family have been
observed [13,30,31,35] and this was evident also in individual cases and cohorts described in
the recent literature (Table 4). Some subjects with rMED have shown clinical manifestations
that are more characteristic for DTD like cleft palate, auricular defects and severe cervical
kyphosis [30,31,35]. The normal or mildly shortened stature seen in rMED can help to
clinically distinguish it from DTD. We observed great variability in the severity of clinical
manifestations among children with DTD with the same mutation, ranging from one very
severe phenotype to milder forms of DTD. The severity of the clinical phenotype has been
associated with the mutation type, the residual activity of the sulfate transporter and the
extent of the under-sulfation of cartilage matrix [6] and some conclusions can be drawn also
based on the recently reported cases (Table 4). However, the mutation type is not the only
factor determining the phenotypic severity since clinical features also show intrafamilial
variability. A large study reported that the severity and development of scoliosis in DTD
cannot be predicted from genotype [57]. The phenotypic variability may be related to
other genes, modifiers altering sulfate metabolism or environmental pre- and postnatal
factors [13,57,62].
The diagnosis of DTD can usually be made prenatally or at birth. The majority of the
children in our cohort were diagnosed with DTD prenatally and the remaining subjects
were diagnosed at birth. Early prenatal diagnosis from DNA from chorionic villus is
possible in subsequent pregnancies because of the 25% recurrence risk.
The main limitations of the study are the retrospective study design, the small cohort
size and a short follow-up time for part of our pediatric cohort. Genetic data was absent
or partial for some children as diagnosis was based on the typical clinical presentation
only or genetic evaluation was performed elsewhere. Furthermore, because of the nature
of our study, we were not able to obtain information regarding pregnancies that have
been terminated in Finland during the past years because of suspected or confirmed DTD.
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However, it is likely that the decreasing incidence is partly explained by improved genetic
counseling and increased prenatal diagnostics. In addition, increasing heterogeneity and
mobility of the Finnish population may impact the incidence of the autosomal diseases
caused by the old founder mutations.
The patient care in DTD requires a multi-disciplinary team in which especially ortho-
pedic expertise is essential. Increased pathophysiological understanding and advances in
the development of pharmacological treatments may hopefully offer individuals with DTD
new therapeutic approaches in the future.
5. Conclusions
We observed a decreasing incidence of DTD in Finland, probably due to advanced
prenatal diagnostics. The variable clinical severity, even in children with the same genotype,
highlights the wide spectrum of clinical manifestations of SLC26A2-related disorders. The
high phenotypic variability related to skeletal dysplasias can complicate the diagnosis.
Genetic testing together with genetic counselling are important parts of the patient care.
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